文献库搜索 | GeneLibs

Li(S),Yao(Z),Yang(Q),Sun(Y),Long(M) Vet Microbiol 2026-09-00

...MOS (1000 mg/kg) groups for 2 weeks. MOS supplementation significantly reduced pulmonary SIV replication, indicated by l...

Sanai(FM),Saati(A),Alghamdi(H),Aldosari(S)... Sci Rep 2026-05-30

...most had intermediate-stage (BCLC B, 54.5%), followed by early-stage (BCLC 0/A, 34.0%) and locally advanced-stage diseas...

Jin(Y),Eppihimer(M),Alam(MS),Powell(AT),Ma... Toxicol Sci 2026-06-05

...MoS) indicating that there is negligible toxicological concern from the presence of metals in tampon materials. This stu...

Moisander(M),Hölsä(O),Teittinen(K),Kyseniu... Ther Adv Urol None

...mOS) for all treated patients was 40.1 months. The mOS of treated patients with mHSPC increased from 32.6 months during ...

Pei(J),Xiao(Z),Deng(Y),Han(Y),Yang(M),Wang... Front Oncol None

...mOS) nor median disease-free survival (mDFS) was reached in the MPR group, while mOS and mDFS in the non-major pathologi...

Khamis(MM),Lapari(MS),Alkharabsheh(O),Bara... Oncologist 2026-06-06

...mOS) difference of -4.5 months (95% CI, -9.1 to 0.0; P = .05) and a pooled median progression-free survival (mPFS) diffe...

Singh(H),Buchfuhrer(MJ),Ojile(J),Roy(A),Th... Sleep 2026-06-03

...MOS-II) score. Adjunctive RLS medications were assessed at study entry and Day 90. A total of 232 patients met criteria ...

Wilsey(J),Potapova(I),Wu(S),Weng(MW),Lewis... Front Toxicol None

...MOS) are low, refined exposure estimates are then derived using in vitro-in vivo correlation (IVIVC) data. Degradation-b...

Jaques(YM),Woellner(CF),Sassi(LM),Pereira ... ACS Nanosci Au 2026-06-17

...MoS2, which yields stable MoS monolayers. Various defect sizes, temperature regimes (300-1000 K), and substrate effects ...

Wang(S),Yang(C),Zhou(Q),Chen(Y),Zhang(C) Front Bioeng Biotechnol None

...MoS. Additionally, a positive correlation was observed between frontal-plane stiffness (p = 0.005, r = 0.361) and the Mo...